MarketCap
Facebook
X
Telegram
Avenue Therapeutics Balance Sheet 2025-2011 | ATXI
Brief balance sheet overview of Avenue Therapeutics
This overview follows the five latest available annual observations between 2021 and 2025.
Across five reporting periods, assets decreased -26%, from $4 million to $2.9 million, producing a negative trend.
Liabilities grew faster than assets: +115.9% versus -26%. A substantial part of expansion was externally funded.
Equity funds 62.5% of assets versus 87.1% initially. This creates a conservative balance sheet structure.
The cash reserve occupies 97.4% of the balance sheet, previously 95%. It is one marker of short-term resilience.
Retained earnings are negative at -$105.5 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
What the balance sheet shows
Avenue Therapeutics's balance sheet looks stretched: reliance on liabilities and a limited capital cushion increase sensitivity to weaker results.
Annual Balance Sheet Avenue Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | -3.13 K | -8.74 M | -2.67 M | -11.8 M | 5.68 M | 3.85 M | - | - | - | - |
Long Term Debt |
- | - | - | - | - | - | - | - | - | 2.03 M | 2.7 M | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | 2.03 M | 2.7 M | - | - | - | - |
Total Current Liabilities |
1.1 M | 816 K | 1.2 M | 3.58 M | 509 K | 886 K | 2.12 M | 5.16 M | 2.79 M | - | - | - | - | - | - |
Total Liabilities |
1.1 M | 816 K | 1.2 M | 3.58 M | 509 K | 886 | 2.12 M | 5.16 M | 2.79 M | 8.44 M | 5.15 M | - | - | - | - |
Retained Earnings |
-105 M | -103 M | -90.9 M | -80.6 M | -77 M | - | -68.1 M | -42.2 M | -20.7 M | -8.4 M | -5.23 M | - | - | - | - |
Total Assets |
2.93 M | 2.67 M | 1.85 M | 6.84 M | 3.96 M | 3.24 K | 8.92 M | 4.52 M | 22.2 M | 197 K | 14 K | - | - | - | - |
Cash and Cash Equivalents |
2.86 M | 2.59 M | 1.78 M | 6.71 M | 3.76 M | 3.13 M | 8.74 M | 2.67 M | 11.8 M | 197 K | - | - | - | - | - |
Book Value |
1.83 M | 1.86 M | 654 K | 3.27 M | 3.45 M | 2.36 K | 6.8 M | -631 K | 19.4 M | -8.25 M | -5.14 M | - | - | - | - |
Total Shareholders Equity |
1.83 M | 2.8 M | 1.58 M | 3.9 M | 3.45 M | 2.36 M | 6.8 M | -631 K | 19.4 M | -8.25 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Avenue Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Liabilities |
1.27 M | 1.42 M | 1.33 M | 1.26 M | 816 K | 973 K | 1.16 M | 1.41 M | 1.2 M | 5.02 M | 7.81 M | 10.6 M | 3.58 M | 614 K | 407 K | 797 K | 509 K | 848 K | 549 K | 469 K | 886 K | 886 K | 886 K | 886 K | 2.12 M | 2.12 M | 2.12 M | 2.12 M | 5.16 M | 5.16 M | 5.16 M | 5.16 M | 2.79 M | 2.79 M | 2.79 M | 2.79 M | 8.44 M | 8.44 M | 8.44 M | 8.44 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-106 M | -105 M | -104 M | -104 M | -103 M | -101 M | -98 M | -95.3 M | -90.9 M | -91.6 M | -92.1 M | -88.1 M | -80.6 M | -81.1 M | -80.5 M | -79.9 M | -77 M | -76.1 M | -75.2 M | -74.3 M | -73.3 M | -73.3 M | -73.3 M | -73.3 M | -68.1 M | -68.1 M | -68.1 M | -68.1 M | -42.2 M | -42.2 M | -42.2 M | -42.2 M | -20.7 M | -20.7 M | -20.7 M | -20.7 M | -8.4 M | -8.4 M | -8.4 M | -8.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
2.47 M | 3.72 M | 4.16 M | 3.59 M | 2.67 M | 2.62 M | 4.99 M | 3.31 M | 1.85 M | 502 K | 1.67 M | 8.45 M | 6.84 M | 575 K | 1 M | 1.96 M | 3.96 M | 688 K | 1.19 M | 1.94 M | 3.24 M | 3.24 M | 3.24 M | 3.24 M | 8.92 M | 8.92 M | 8.92 M | 8.92 M | 4.52 M | 4.52 M | 4.52 M | 4.52 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 197 K | 197 K | 197 K | 197 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
2.42 M | 3.71 M | 3.33 M | 3.5 M | 2.59 M | 2.6 M | 4.92 M | 3.19 M | 1.78 M | 161 K | 1.57 M | 8.24 M | 6.71 M | 217 K | 890 K | 1.83 M | 3.76 M | 585 K | 1.12 M | 1.82 M | 3.13 M | 3.13 M | 3.13 M | 3.13 M | 8.74 M | 8.74 M | 8.74 M | 8.74 M | 2.67 M | 2.67 M | 2.67 M | 2.67 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 197 K | 197 K | 32 K | 197 K | 14 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.2 M | 2.3 M | 2.83 M | 2.33 M | 1.86 M | 1.65 M | 3.83 M | 1.9 M | 654 K | -4.52 M | -6.15 M | -2.16 M | 3.27 M | -39 K | 598 K | 1.16 M | 3.45 M | -160 K | 642 K | 1.48 M | 2.36 M | 2.36 M | 2.36 M | 2.36 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | -631 K | -631 K | -631 K | -631 K | 19.4 M | 19.4 M | 19.4 M | 19.4 M | -8.25 M | -8.25 M | -8.25 M | -8.25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.2 M | 3.56 M | 4.06 M | 3.51 M | 2.8 M | 1.65 M | 3.83 M | 1.9 M | 1.58 M | -4.52 M | -6.15 M | -2.16 M | 3.9 M | -39 K | 598 K | 1.16 M | 3.45 M | -160 K | 642 K | 1.48 M | 2.36 M | 2.36 M | 2.36 M | 2.36 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | -631 K | -631 K | -631 K | -631 K | 19.4 M | 19.4 M | 19.4 M | 19.4 M | -8.25 M | -8.25 M | -8.25 M | -8.25 M | -5.14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Avenue Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Germany
China
Israel
France
Britain
Belgium
